Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

6.960 -0.530 (-7.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,190,127
Open 7.520
Bid (Size) 6.670 (200)
Ask (Size) 6.780 (1,000)
Prev. Close 7.490
Today's Range 6.920 - 7.550
52wk Range 2.710 - 8.850
Shares Outstanding 348,875,959
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
From Agenus Inc.
Via Business Wire

Performance

YTD
+115.5%
+115.5%
1 Month
+98.9%
+98.9%
3 Month
+85.6%
+85.6%
6 Month
+151.3%
+151.3%
1 Year
+46.2%
+46.2%

More News

Read More
News headline image
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
From Agenus Inc.
Via Business Wire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
Sphere 3D (NASDAQ: ANY) Engages Specialized Government Affairs Firms, Expands AI Infrastructure Strategy Across Tennessee Valley Authority Region
Via AB Newswire
Topics Artificial Intelligence
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
Discover the most active stocks in Monday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
Top stock movements in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing ↗
Via MarketBeat
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves ↗
Via MarketBeat
News headline image
Agenus Announces Virtual 2026 Annual Shareholders Meeting
From Agenus Inc.
Via Business Wire
News headline image
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
From Agenus Bio
Via Business Wire
News headline image
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
From Agenus Inc. & BAP Pharma
Via Business Wire
News headline image
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
From Agenus Inc.
Via Business Wire

Frequently Asked Questions

Is Agenus Inc. - Common Stock publicly traded?
Yes, Agenus Inc. - Common Stock is publicly traded.
What exchange does Agenus Inc. - Common Stock trade on?
Agenus Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Agenus Inc. - Common Stock?
The ticker symbol for Agenus Inc. - Common Stock is AGEN on the Nasdaq Stock Market
What is the current price of Agenus Inc. - Common Stock?
The current price of Agenus Inc. - Common Stock is 6.960
When was Agenus Inc. - Common Stock last traded?
The last trade of Agenus Inc. - Common Stock was at 08/07/26 04:00 PM ET
What is the market capitalization of Agenus Inc. - Common Stock?
The market capitalization of Agenus Inc. - Common Stock is 2.43B
How many shares of Agenus Inc. - Common Stock are outstanding?
Agenus Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.